Table 1: Clinical Data (N = 62).
|
|
N (%) |
|
Median age (range;year) |
22.0 (4-34) |
|
Parity before surgery 0 1 2 |
48 (77.4) 8 (12.9) 6 (9.7) |
|
Presentation Pelvic mass Abdominal pain Abdominal distension Others* |
24 (38.7) 18 (29.0) 15 (24.2) 5 (8.1) |
|
Tumor side Right Left Bilateral |
34 (54.8) 26 (41.9) 2 (3.2) |
|
Detail of FSS Unilateral SO Unilateral cystectomy Unilateral SO & cystectomy |
49 (79.0) 4 (6.5) 9 (14.5) |
|
Frozen section |
26 (41.9) |
|
Cytology Not done Negative Positive |
23 (37.1) 29 (46.8) 10 (16.1) |
|
Omentectomy Not done Negative positive |
18 (29.0) 40 (64.5) 4 (6.5) |
|
Lymphadenectomy Not done Negative Positive |
32 (51.6) 26 (41.9) 4 (6.5) |
|
Appendectomy |
32 (51.6) |
|
Surgical outcome No residual Optimal Suboptimal (residual tumor > 1 cm) |
47 (75.8) 5 (8.1) 10 (16.1) |
|
Histology Dysgerminoma Immature teratoma Yolk sac tumor Mixed type Others# |
17 (27.4) 20 (32.3) 15 (24.2) 5 (8.1) 5 (8.1) |
|
Stage I II III IV |
46 (74.2) 6 (9.7) 7 (11.3) 3 (4.8) |
|
Adjuvant chemotherapy None BEP EMACO |
19 (30.6) 42 (67.7) 1 (1.6) |
|
Cycle of chemotherapy 1-3 4-6 > 6 |
6 33 4 |
|
Long term side effect None Numbness Lung fibrosis High frequency hearing loss Tinnitus |
46 (74.2) 3 (4.8) 2 (3.2) 1 (1.6) 1 (1.6) |
|
Progression of disease |
4 (9.5) |
|
Death Alive Missing data |
5 (8.1) 55 (88.7) 2 (3.2) |
*Others presentation: amenorrhea (2), anti-NMDAR (N-methyl D-aspartate receptors) encephalitis (1), incidental finding during cesarean section (1), hyperthyroidism (1)
#Others histology: strumaovarii (1), carcinoid (1), chorioCA (1), steroid cell tumor (1), Papillary thyroid CA arising in teratoma (1))
Death sn 43,52,74,108,110
SO; Salpingo-Oophorectomy, BEP; Bleomycin+Etoposide+Cisplatin, EMACO; Etoposide+Methotrexate+Actinomycin D + Cyclophosphamide + Vincristine